ARTICLE | Company News
AstraZeneca sales and marketing update
July 27, 2015 7:00 AM UTC
The U.K.’s NICE issued preliminary draft guidance recommending against the use of Lynparza olaparib from AstraZeneca for maintenance treatment of ovarian, fallopian tube or primary peritoneal cancer....